Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.75 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26829682 | 0.98 | PDGFRB (0.72) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL24621829 | 0.98 | PDGFRB (0.72) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL29375510 | 0.98 | PDGFRB (0.72) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL12074709 | 0.96 | PDGFRB (0.70) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL32667946 | 0.93 | PDGFRB (0.77) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL2772360 | 0.93 | PDGFRB (0.77) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL12580402 | 0.92 | PDGFRB (0.66) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL12580411 | 0.92 | PDGFRB (0.66) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL12580362 | 0.92 | PDGFRB (0.66) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL12580354 | 0.92 | PDGFRB (0.66) | PDGFRBPDGFRACYP2A6BIRC5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112250628-B | Method for preparing tetrahydroquinoline compound by catalytic hydrogenation of ruthenium catalyst | 上海应用技术大学 | 2022-07-08 | — | — | CN | claimed |
| CN-110615815-B | Novel metal complex photosensitizer with broad-spectrum tumor phototherapeutic activity and preparation method and application thereof | 中山大学 | 2022-03-04 | — | — | CN | claimed |
| CN-112250628-A | Method for preparing tetrahydroquinoline compound by catalytic hydrogenation of ruthenium catalyst | 上海应用技术大学 | 2021-01-22 | — | — | CN | claimed |
| CN-110615815-A | Novel metal complex photosensitizer with broad-spectrum tumor phototherapeutic activity and preparation method and application thereof | 中山大学 | 2019-12-27 | — | — | CN | claimed |
| CN-101906072-A | 3-phenylquinoline compounds as well as preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2010-12-08 | — | — | CN | claimed |
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-04-03 | — | — | US | claimed |
| CN-1400904-A | Selective estrogen receptor modulators in combination with estrogens | ENDORECH INC (CA) | 2003-03-05 | — | — | CN | claimed |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-02-27 | — | — | US | claimed |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2002-12-26 | — | — | US | claimed |
| EP-1251855-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | Endorecherche, Inc. (CA) | 2002-10-30 | — | — | EP | claimed |
| WO-2001054699-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | ENDORECHERCHE, INC. (CA) | 2001-08-02 | — | — | WO | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12084421-B2 | Quinoline-based proteasome inhibitors and uses thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-115710223-B | Preparation method of 3-aryl quinolinone derivative | 广东工业大学 | 2024-05-10 | — | — | CN | disclosed |
| EP-0025598-B1 | THE USE OF 2-PHENYLTETRALIN DERIVATIVES, OR HETEROCYCLIC ANALOGUES, IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-08-01 | — | — | EP | disclosed |
| EP-0025598-A1 | The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
| US-4135045-A | PROCESS FOR POLYMERIZATION OF OLEFINS AND CATALYST COMPOSITION THEREFOR | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1979-01-16 | — | — | US | disclosed |
| US-4048415-A | TITANIUM-ALUMINUM COORDINATION CATALYSTS | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JA) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084421-B2 | Quinoline-based proteasome inhibitors and uses thereof | PSME1, PSMB1, PSME3 | PDGFRB 3335/4885PDGFRA 3555/4885CYP2A6 3496/4885 |
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ESR1, BRCA1, KISS1R | PDGFRB 250/4885PDGFRA 258/4885CYP2A6 920/4885 |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | PDGFRB 160/4885PDGFRA 184/4885CYP2A6 812/4885 |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | PDGFRB 160/4885PDGFRA 184/4885CYP2A6 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.